Screener
Ligand Pharmaceuticals LGND Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues and income by Product | ||||||
| Captisol | $7.98M-3.7% | $8.65M-35.7% | $7.79M-1.5% | $10.67M+70.6% | $8.29M+10.5% | |
| Capvaxive | $2.32M+2.9% | $1.97M+122% | $3.72M+1,847% | $3.21M+637% | $2.25M— | |
| Contract revenue | $2.68M+39.3% | $110K-97.5% | $60.43M+2,873% | $131K-99.1% | $1.93M— | |
| Filspari | $13.57M+106% | $11.32M+114% | $11.01M+131% | $9.08M+183% | $6.58M+171% | |
| Kyprolis | $7.04M-20.0% | $6.74M+42.7% | —— | $11.62M+0.2% | $8.8M-2.2% | |
| Ohtuvayre inventors | $3.29M— | $3.05M— | —— | —— | $0— | |
| Ohtuvayre | $4.14M+98.8% | $2.99M+112% | —— | —— | $2.08M— | |
| Other | $4.27M+66.5% | $3.76M+2.5% | —— | $3.42M+98.3% | $2.56M+27.9% | |
| Qarziba | $6.15M+4.5% | $6.3M+15.7% | $6.44M-0.9% | $5.98M+29.1% | $5.89M— | |
| Rylaze | $3.2M+11.8% | $3.22M+3.3% | —— | $3.56M-8.5% | $2.86M-11.4% | |
| Teriparatide injection | $1.47M-36.0% | $1.32M+10.9% | —— | $2.63M+10.8% | $2.3M+9.3% | |
| Vaxneuvance | $1.35M-48.9% | $1.61M+25.3% | $1.44M+17.5% | $2.04M+39.1% | $2.64M+138% |
FAQ
- How does Ligand Pharmaceuticals break its business down?
- Ligand Pharmaceuticals (LGND) reports total revenues and income by product across 12 parts — Captisol, Capvaxive, Contract revenue, Filspari and Kyprolis. Each is extracted from the segment footnotes and tracked over time.
- Where does Ligand Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ligand Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
